Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bluebird Bio (BLUE) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Salveen Richter saying rating change is is not driven by concerns around Bluebird's pipeline execution or emerging competitive threats. The analyst just believes appreciation of key aspects of his investment thesis are better reflected in the shares at current valuation levels. 2. Venator Materials (VNTR) downgraded to Neutral from Overweight at JPMorgan with analyst Jeffrey Zekauskas saying he believes lower prices and higher raw material costs for TiO2, coupled with higher capital expenditures, diminishes Venator's free cash flow outlook. 3. Antero Resources (AR) downgraded to Market Perform from Outperform at BMO Capital with analyst Phillip Jungwirth citing valuation. 4. New Age Beverages (NBEV) downgraded to Hold from Buy at Maxim. 5. Rowan Companies (RDC) downgraded to Hold from Buy at HSBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Reports Q1 revenue $1.122B, consensus $1.06B. Paul Rady, Chairman, CEO and President of Antero Resources commented, "The improved capital efficiency realized in 2023 continues in 2024. Our consistent focus on operations from our drilling and completion teams once again led to new Company records during the quarter. In the month of March, we set records for most completion stages per day at 12.6 stages per day and most pumping hours for a single completion crew in a month at 588 hours. These were both 7% higher than our previous monthly records. Our capital efficiency and focus on liquids development drove a sequential increase in liquids volumes and led to the production guidance increase for 2024. Further, this growth was achieved while running only two drilling rigs and one completion crew."

Pre-earnings options volume in Antero Resources is 1.5x normal with calls leading puts 7:4. Implied volatility suggests the market is anticipating a move near 3.6%, or $1.12, after results are released. Median move over the past eight quarters is 3.4%.